Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus

Jungang Chen, Lu Dai, Lindsey Barrett, Steven R. Post, Zhiqiang Qin
doi: https://doi.org/10.1101/2020.10.02.324228
Jungang Chen
1Departments of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lu Dai
1Departments of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsey Barrett
1Departments of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven R. Post
1Departments of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiqiang Qin
1Departments of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zqin@uams.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Summary

An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of Coronavirus Disease-2019 (COVID-19), a respiratory disease, has infected over 34,000,000 people since the end of 2019, killed over 1,000,000, and caused worldwide social and economic disruption. Due to the mechanisms of SARS-CoV-2 infection to host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Besides severe respiratory and systematic symptoms, several comorbidities may also increase risk of fatal disease outcome. Therefore, it is required to investigate the impacts of COVID-19 on pre-existing diseases of patients, such as cancer and other infectious diseases. In the current study, we have reported that SARS-CoV-2 encoded proteins and some anti-COVID-19 drugs currently used are able to induce lytic reactivation of Kaposi’s sarcoma-associated herpesvirus (KSHV), one of major human oncogenic viruses through manipulation of intracellular signaling pathways. Our data indicate that those KSHV+ patients especially in endemic areas exposure to COVID-19 or undergoing the treatment may have increased risks to develop virus-associated cancers, even after they have fully recovered from COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 02, 2020.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
Jungang Chen, Lu Dai, Lindsey Barrett, Steven R. Post, Zhiqiang Qin
bioRxiv 2020.10.02.324228; doi: https://doi.org/10.1101/2020.10.02.324228
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
Jungang Chen, Lu Dai, Lindsey Barrett, Steven R. Post, Zhiqiang Qin
bioRxiv 2020.10.02.324228; doi: https://doi.org/10.1101/2020.10.02.324228

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Microbiology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4079)
  • Biochemistry (8750)
  • Bioengineering (6467)
  • Bioinformatics (23315)
  • Biophysics (11719)
  • Cancer Biology (9135)
  • Cell Biology (13227)
  • Clinical Trials (138)
  • Developmental Biology (7404)
  • Ecology (11360)
  • Epidemiology (2066)
  • Evolutionary Biology (15078)
  • Genetics (10390)
  • Genomics (14001)
  • Immunology (9109)
  • Microbiology (22025)
  • Molecular Biology (8773)
  • Neuroscience (47317)
  • Paleontology (350)
  • Pathology (1419)
  • Pharmacology and Toxicology (2480)
  • Physiology (3701)
  • Plant Biology (8044)
  • Scientific Communication and Education (1427)
  • Synthetic Biology (2206)
  • Systems Biology (6009)
  • Zoology (1247)